SEC Form 4 · accession 0000899243-17-027824
X4 Pharmaceuticals, Inc · XFOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michael Jay Ross
Director · 10% Owner
Period of report
Nov 15, 2017
Accepted (ET)
Dec 1, 2017 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501697
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $10.00 | Nov 15, 2017 | A | 7,324 | A | — | Nov 14, 2027 | Common Stock | 7,324 | 7,324 | D |
Explanation of responses
- F1Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program.
- F2The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.